



# Bridging the Gap to CAR-T



A caregiver's  
perspective on access  
and waiting time

*Caregiver's Perspective – May 7<sup>th</sup>, 2026*



CAR-T therapy offers hope.  
But the journey to treatment is often complex:

1. Referral pathways
2. Eligibility criteria
3. Manufacturing timelines

For many families, this means critical waiting periods.



# Access is more than availability:

It is:

- coordinated,
- timely,
- equitable

delivery of therapy.

From a caregiver perspective, timing is everything.




# Listening to caregivers



Betsy Larrabee  
Pediatric Cancer  
Advocate | Writer  
| Speaker

We wanted to understand  
the caregiver perspective  
and exchanged with  
Betsy Larrabee  
from Denver, Colorado US

Learn more about  
Betsy and her family  
via her channels



Website  
[Theheavywait.com](https://Theheavywait.com)



Betsy Larrabee's  
[LinkedIn](#)

*Caregiver's Perspective – May 7<sup>th</sup>, 2026*



How did the waiting time for CAR-T therapy impact your loved one's condition and your daily life?

*„This isn't just waiting, it's delaying a childhood. Life narrows to labs and symptoms instead of the normal joys of a child being a child.“*

- Betsy Larrabee | Caregiver




Betsy Larrabee and her son Beaudin, who received CAR-T therapy for ALL in 2021



What were your biggest concerns during the manufacturing and scheduling period?

*„Our biggest concern was if our choice to wait on novel science (CAR T manufacturing) would allow the disease to progress to a point that we couldn't manage it.“*

*- Betsy Larrabee | Caregiver*



What kind of support or transparency would have improved your experience during the wait?

*„Connection to other parents and patients who have lived it would have changed the waiting experience. Seeing others on the other side helps you understand this treatment as a path to cure, not just an experiment of hope.“*

*- Betsy Larrabee | Caregiver*

*Caregiver's Perspective – May 7<sup>th</sup>, 2026*



# Why this matters to EASYGEN

At EASYGEN, we believe innovation  
in CAR-T must go beyond science.

It must reach patients in time.

Because access delayed can mean  
opportunity lost.



# EASYGEN aims to advance CAR-T ecosystems by:

 Improving patient access pathways

 Addressing system bottlenecks

 Enabling more timely treatment

Because innovation only matters when it reaches patients at the right time.



Let's work together to:

- Reduce waiting times
- Strengthen care coordination
- Support caregivers

Faster access is  
better care.



The EASYGEN „EASY workflow integration for GENE therapy“ consortium (Grant ID: 101194710) is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

